# 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR $\ S 8 0 7 . 9 2$ .

The assigned 510(k) number is: K080635.

# Submitted By:

Medtox Diagnostics, Inc. 1238 Anthony Road Burlington, North Carolina 27215

# Contact Person:

Phillip Hartzog, Ph.D. Director, Research & Development Phone: 336-226-6311, ext. 2863 Fax: 336-229-4471

Date Prepared: February 10, 2009

Proprietary Name: PROFILE®-V MEDTOXScan® Drugs of Abuse Test System

Common Name: Colorimeter, Drugs of Abuse Test System

# Classification Names:

The applicant test system regulatory classification is Class I; the Classification Panel is Clinical Toxicology (91) and Clinical Chemistry (75). Regulatory. information applicable to the test system is provided below:

<table><tr><td rowspan=1 colspan=1>CFR Section</td><td rowspan=1 colspan=1>Product Code</td></tr><tr><td rowspan=1 colspan=1>862.2300, Colorimeter, Photometer, Spectrophotometer for Clinical Use</td><td rowspan=1 colspan=1>JJQ</td></tr><tr><td rowspan=1 colspan=1>862.3100, Amphetamine Test System</td><td rowspan=1 colspan=1>DKZ</td></tr><tr><td rowspan=1 colspan=1>862.3150, Barbiturate Test System</td><td rowspan=1 colspan=1>DIS</td></tr><tr><td rowspan=1 colspan=1>862.3170, Benzodiazepine Test System                               1</td><td rowspan=1 colspan=1>JXM</td></tr><tr><td rowspan=1 colspan=1>862.3250, Cocaine and cocaine metabolite Test System</td><td rowspan=1 colspan=1>DIO</td></tr><tr><td rowspan=1 colspan=1>862.3620, Methadone Test System</td><td rowspan=1 colspan=1>DJR</td></tr><tr><td rowspan=1 colspan=1>862.3610, Methamphetamine Test System</td><td rowspan=1 colspan=1>DJC</td></tr><tr><td rowspan=1 colspan=1>862.3650, Opiate Test System</td><td rowspan=1 colspan=1>DJG</td></tr><tr><td rowspan=1 colspan=1>862.3100, Amphetamine Test System (Phencyclidine)</td><td rowspan=1 colspan=1>LCM</td></tr><tr><td rowspan=1 colspan=1>862.3870, Cannabinoid Test System</td><td rowspan=1 colspan=1>LDJ</td></tr></table>

Predicate Device: Triage® Meter (K973547)

# Description of the Device

The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System consists of the PROFILE®-V MEDTOXScan® Test Devices and the MEDTOXScan® Reader. The MEDTOXScan® Reader is an instrument used as an aid in determining the presence or absence of a colored line associated with the PROFILE®-V MEDTOxScan® one-step drugs of abuse qualitative screening immunoassays for the detection of one or more of the following in human urine: Amphetamine, Barbiturates, Benzodiazepines, Cocaine, Methadone,  Methamphetamine, Opiates, Phencyclidine, and THC (Cannabinoids) or their metabolites.

The MEDTOxScan® reader scans the device and utilizes a contact imaging sensor (CIS) to capture relative line intensities. Software algorithms and barcodes are used to identify the type of device to be read, the analyte(s) associated with the device and whether the presence or absence of a line is associated with a negative or positive result.The results of the scans are displayed on the MEDTOXScan® screen or optionally can be printed. The PROFILE®-V MEDTOxScan® Test Devices cannot be visually read.

# Intended Use

The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System consists of the PROFILE®-V MEDTOXScan® Test Devices and the MEDTOXScan® Reader. The PROFILE®V MEDTOxScan® Test Devices are one-step immunochromatographic tests for the rapid, qualitative detection of one or more of the following in human urine: Amphetamine, Barbiturates, Benzodiazepines, Cocaine, Methadone, Methamphetamine, Opiates, Phencyclidine and THC (Cannabinoids) or their metabolites.The PROFILE®V MEDTOXScan Test Devices can only be used with the MEDTOXScan® Reader. The MEDTOXScan® Reader is an instrument used to interpret and report the results of the ROFILE®V MEDTOXScan® Test Device. The PROFILE®-V MEDTOXScan® Test Devices cannot be visually read.

The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System is for in vitro diagnostic use and is intended for professional use only. It is not intended for use in point-of-care settings.

The PROFILE®-V MEDTOxScan® Drugs of Abuse Test System detects drug classes at the following cutoff concentrations:

<table><tr><td rowspan=1 colspan=1>AMP Amphetamine (d-Amphetamine)</td><td rowspan=1 colspan=1>500 ng/mL</td></tr><tr><td rowspan=1 colspan=1>BAR Barbiturates (Butalbital)</td><td rowspan=1 colspan=1>200 ng/mL</td></tr><tr><td rowspan=1 colspan=1>BZO Benzodiazepines (Nordiazepam)</td><td rowspan=1 colspan=1>150 ng/mL</td></tr><tr><td rowspan=1 colspan=1>COC Cocaine (Benzoylecgonine)</td><td rowspan=1 colspan=1>150 ng/mL</td></tr><tr><td rowspan=1 colspan=1>MAMP Methamphetamine (d-Methamphetamine)</td><td rowspan=1 colspan=1>500 ng/mL</td></tr><tr><td rowspan=1 colspan=1>MTD Methadone (Methadone)</td><td rowspan=1 colspan=1>200 ng/mL</td></tr><tr><td rowspan=1 colspan=1>OPI Opiates (Morphine)</td><td rowspan=1 colspan=1>100 ng/mL</td></tr><tr><td rowspan=1 colspan=1>PCP Phencyclidine (Phencyclidine)</td><td rowspan=1 colspan=1>25 ng/mL</td></tr><tr><td rowspan=1 colspan=1>THC Cannabinoids(11-nor-9-carboxy-49-THC)</td><td rowspan=1 colspan=1>50 ng/mL</td></tr></table>

Configurations of the PROFILE®-V MEDTOXScan® Test Devices may consist of any combination of the above listed drug analytes. Refer to specific product labeling for the combination of drug tests included on that test device.

THE PROFILE®-V MEDTOXSCaN® DRUGS OF ABUSE TEST SYSTEM PROVIDES ONLY A PRELIMINARY ANALYTICAL TEST RESULT. A MORE SPECIFIC ALTERNATE CHEMICAL METHOD MUST BE USED IN ORDER TO OBTAIN A CONFIRMED ANALYTICAL RESULT. GAS CHROMATOGRAPHY / MASS SPECTROMETRY (GC/MS), HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) OR LIQUID CHROMATOGRAPHY / TANDEM MASS SPECTROMETRY (LC/MS/MS) ARE THE PREFERRED CONFIRMATORY METHODS. CLINICAL CONSIDERATION AND PROFESSIONAL JUDGMENT SHOULD BE APPLIED TO ANY DRUG OF ABUSE TEST RESULT, PARTICULARLY WHEN PRELIMINARY POSITIVE RESULTS ARE OBTAINED.

The MEDTOxScan® Reader includes a Positive QC Test Device, a Negative QC Test Device and a Cleaning Cassette. The MEDTOXScan® Positive and Negative QC Test Devices are intended to detect errors associated with the MEDTOxScan® Reader and a contaminated contact imaging sensor (CIS), and to verify that the CIS cleaning procedure using the MEDToxScan® Cleaning Cassette effectively removed any contamination (see Troubleshooting" Section).

# Discussion of Technological Characteristics:

# a. Similarities and differences to predicate device

Both the applicant and the predicate test systems are used to detect the presence of drugs of abuse and their metabolites in human urine. In both systems, a urine sample is added to the test device and allowed to react for a specified period of time, after which an instrument is used to read the test device and interpret and display the test result. Both the applicant and predicate test devices are rapid single use disposable devices that use immunochromatographic lateral flow technology. The applicant test device utilizes gold-conjugated reagents to generate the reddish-purple test and controls lines, which are read by the instrument. The predicate test device uses fluorescent-conjugated reagents to generate control and test lines that are not visible and can be read only by the instrument.

Overall performance and characteristics of the MEDTOxScan® and the predicate device, the Triage Meter, are summarized in Table 1 below:   

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Determines qualitative positive ornegative result from drug of abuseimmunoassay screens.</td><td rowspan=1 colspan=1>Determines qualitative positive ornegative result from drug of abuseimmunoassay screens.</td></tr><tr><td rowspan=1 colspan=1>SystemProcedure</td><td rowspan=1 colspan=1>Sample is added to a single usetest cassette, which is then read byinstrument. Instrument is designedto read multiple single use testcassettes, one at a time.</td><td rowspan=1 colspan=1>Sample is added to a single use testcassette, which is then read byinstrument. Instrument is designed toread multiple single use testcassettes, one at a time.</td></tr><tr><td rowspan=1 colspan=1>MeasurementMethod</td><td rowspan=1 colspan=1>Scans the single-use test cassetteto detect a signal.</td><td rowspan=1 colspan=1>Scans the single-use test cassette todetect a signal.</td></tr><tr><td rowspan=1 colspan=1>Output</td><td rowspan=1 colspan=1>Outputs &quot;positive,&quot; &quot;negative,&quot; and&quot;invalid&quot; test results on paperprintout or LCD screen.</td><td rowspan=1 colspan=1>Outputs &quot;positive,, &quot;and &quot;negative,&quot;test results on paper printout.</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Single-UseTest Cassette</td><td rowspan=1 colspan=1>Produces colored lines on device.</td><td rowspan=1 colspan=1>Produces a fluorescent signal that isnot visible to the instrument operator.</td></tr><tr><td rowspan=1 colspan=1>Assay Type</td><td rowspan=1 colspan=1>Competitive assay whereconcentration of drug is inverselyrelated to the visible signaldetected by the instrument.</td><td rowspan=1 colspan=1>Competitive assay whereconcentration of drug is inverselyrelated to the fluorescent signaldetected by the instrument.</td></tr><tr><td rowspan=1 colspan=1>DetectionMethod</td><td rowspan=1 colspan=1>Measures reflectance of visiblelines on single use test cassette.</td><td rowspan=1 colspan=1>Measures fluorescent signal on singleuse test cassette.</td></tr></table>

Table 1. Comparison of Similarities and Differences for the MEDTOXScan reader and predicate device.

# Discussion of Non-Clinical Tests Performed for Determination of Substantial Equivalence:

Numerous laboratory performance studies were conducted to determine the substantial equivalence of the MEDTOXScan® test to the Triage Meter. These studies are as follows:

Performance of the PROFILE®-V MEDTOXScan® Drugs of Abuse Test System around the specific cutoff for each drug was evaluated by testing standard drug solutions diluted in drug-free urine in triplicate on 5 different intervals by 3 in-house operators using different readers (45 determinations for each level). Drug free urine was also tested on each interval. The results were interpreted at ten minutes by the MEDTOxScan® Reader and are summarized for each drug in Table 2 below:

Table 2. Sensitivity/Precision/ Distribution of Random Error   

<table><tr><td rowspan=1 colspan=1>SampleConcentration(ng/mL)</td><td rowspan=1 colspan=1>% ofCutoff</td><td rowspan=1 colspan=1>Number ofObservations</td><td rowspan=1 colspan=1>#Neg</td><td rowspan=1 colspan=1>#Pos</td><td rowspan=1 colspan=1>SampleConcentration(ng/mL)</td><td rowspan=1 colspan=1>% ofCutoff</td><td rowspan=1 colspan=1>Number ofObservations</td><td rowspan=1 colspan=1># Neg</td><td rowspan=1 colspan=1># Pos</td></tr><tr><td rowspan=1 colspan=5>AMP (500)</td><td rowspan=1 colspan=5>BAR (200)</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>20%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>75%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>75%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>125%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>625</td><td rowspan=1 colspan=1>125%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>150%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>150%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=5>BZO (150)</td><td rowspan=1 colspan=5>COC (150)</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>112.5</td><td rowspan=1 colspan=1>75%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>112.5</td><td rowspan=1 colspan=1>75%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>187.5</td><td rowspan=1 colspan=1>125%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>187.5</td><td rowspan=1 colspan=1>125%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>150%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>150%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=5>mAMP (500)</td><td rowspan=1 colspan=5>MTD (200)</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>20%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>. 50</td><td rowspan=1 colspan=1>25%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>75%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>75%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>37</td></tr><tr><td rowspan=1 colspan=1>625</td><td rowspan=1 colspan=1>125%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>125%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>150%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>150%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=5>OPI (100)</td><td rowspan=1 colspan=5>PCP (25)</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>25%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6.25</td><td rowspan=1 colspan=1>25%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>75%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>18.75</td><td rowspan=1 colspan=1>75%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>44</td></tr><tr><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>125%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>31.25</td><td rowspan=1 colspan=1>125%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>150%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>37.5</td><td rowspan=1 colspan=1>150%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=6 colspan=10>THC (50)0        NEG        45         45    025        50%        45         45     037.5       75%        45         39     662.5      125%       45          0     4575        150%       45         0     45</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>37.5</td><td rowspan=1 colspan=1>75%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>62.5</td><td rowspan=1 colspan=1>125%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>150%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td></tr></table>

Other Technical Performance Documentation for the MEDTOXScan® include:

Influence of Temperature   
Influence of Humidity   
Factory Calibration   
Electrical and EMC Testing   
Validation and stability of QC Control Cassette   
Validation and stability of Cleaning Cassette

Analytical specificity (cross reactivity and interference) data are summarized below.

# Related Compounds and Cross Reactants

The following metabolites and reacting compounds were evaluated for the specified test on the PROFILE®-V MEDTOXScan® Drugs of Abuse Test System. Reference standards for the various metabolites and compounds were prepared in negative urine samples. Results are expressed as the minimum concentration required to produce a positive result in the indicated assay. Compounds that reacted with the test are listed first, and related compounds that did not react with the highest concentration tested are listed second as Negative at 100,000 ng/mL. The $" \%$ Cross-Reactive" values were calculated from the cut-off level for the calibrator used for each test (approximate $50 \%$ positive rate) divided by the lowest reported level found to react in the same test (greater than $6 6 \%$ positive rate).

Amphetamine- (AMP) (d-Amphetamine) 500 nq/mL   

<table><tr><td>I-Amphetamine</td><td>Result Positive at 50,000 ng/mL</td><td>% Cross-Reactive 1%</td></tr><tr><td>Fenfluramine</td><td>Positive at 10,000 ng/mL</td><td>5%</td></tr><tr><td>MDA</td><td>Positive at 250 ng/mL</td><td>200%</td></tr><tr><td>Phentermine</td><td>Positive at 7,500 ng/mL</td><td>7%</td></tr><tr><td></td><td></td><td></td></tr><tr><td>Ephedrine</td><td>Negative at 100,000 ng/mL</td><td>None Detected</td></tr><tr><td>MDE (MDEA)</td><td>Negative at 100,000 ng/mL</td><td>None Detected</td></tr><tr><td>MDMA</td><td>Negative at 100,000 ng/mL</td><td>None Detected</td></tr><tr><td>I-Methamphetamine</td><td>Negative at 100,000 ng/mL</td><td>None Detected</td></tr><tr><td>d-Methamphetamine</td><td>Negative at 100,000 ng/mL</td><td>None Detected</td></tr><tr><td>Phenethylamine</td><td>Negative at 100,000 ng/mL</td><td>None Detected</td></tr><tr><td>Pseudoephedrine</td><td>Negative at 100,000 ng/mL</td><td>None Detected</td></tr><tr><td>Tyramine</td><td>Negative at 100,000 ng/mL</td><td>None Detected</td></tr><tr><td>Barbiturate-(BAR) (Butalbital) 200 ng/mL</td><td>Result</td><td>% Cross-Reactive</td></tr><tr><td>Allobarbital</td><td>Positive at 250 ng/mL</td><td>80%</td></tr><tr><td>Amobarbital</td><td>Positive at 800 ng/mL</td><td>25%</td></tr><tr><td>Barbital</td><td>Positive at 2,500 ng/mL</td><td>8%</td></tr><tr><td>Butabarbital</td><td>Positive at 400 ng/mL</td><td>50%</td></tr><tr><td>Cyclopentobarbital</td><td>Positive at 250 ng/mL</td><td>80%</td></tr><tr><td>DiphenyIhydantoin (Phenytoin)</td><td>Positive at 2,000 ng/mL</td><td></td></tr><tr><td>Pentobarbital</td><td></td><td>10%</td></tr><tr><td>Phenobarbital</td><td>Positive at 300 ng/mL</td><td>67%</td></tr><tr><td></td><td>Positive at 1,250 ng/mL</td><td>16%</td></tr><tr><td>Secobarbital</td><td>Positive at 50 ng/mL</td><td>400%</td></tr><tr><td>Talbutal</td><td>Positive at 50 ng/mL</td><td>400%</td></tr><tr><td>Barbituric Acid</td><td>Negative at 100,000 ng/mL</td><td>None Detected</td></tr><tr><td>Glutethimide</td><td>Negative at 100,000 ng/mL</td><td>None Detected</td></tr><tr><td>Hexobarbital</td><td></td><td>None Detected</td></tr><tr><td></td><td>Negative at 100,000 ng/mL</td><td>None Detected</td></tr><tr><td>Mephobarbital</td><td>Negative at 100,000 ng/mL</td><td></td></tr><tr><td>Thiopental</td><td>Negative at 100,000 ng/mL</td><td>None Detected</td></tr></table>

Alprazolam   
Alprazolam, 1-0H   
Clobazam   
Clonazepam   
Clorazepate   
Desalkylflurazepam   
Desmethylchlordiazepoxide   
Desmethylflunitrazepam   
Diazepam   
Flunitrazepam   
Lorazepam   
Lorazepam glucuronide   
Midazolam   
Nitrazepam   
Oxazepam   
Oxazepam glucuronide   
Temazepam   
Temazepam glucuronide   
Triazolam   
Triazolam, 1-0H

# Result

Positive at 100 ng/mL Positive at 25,000 ng/mL Positive at 75 ng/mL Positive at 900 ng/mL Positive at 200 ng/mL Positive at 600 ng/mL Positive at 1,000 ng/mL Positive at 75 ng/mL Positive at 75 ng/mL Positive at 50 ng/mL Positive at 1,200 ng/mL Positive at 1,000 ng/mL Positive at 5,000 ng/mL Positive at 50 ng/mL Positive at 200 ng/mL Positive at 2,500 ng/mL Positive at 90 ng/mL Positive at 750 ng/mL Positive at 750 ng/mL Positive at 10,000 ng/mL

Cross-Reactive150%<1%200%17%75%25%15%200%200%300%13%15%3%300%EPY $7 5 \%$ EPY6%$167 \%$ EPY$20 \%$ EPYEPY $20 \%$ EPYEPY $2 \%$ EPY

7-Aminoclonazepam 7-Aminoflunitrazepam Chlordiazepoxide Flurazepam

Negative at 100,000 ng/mL None Detected Negative at 100,000 ng/mL None Detected Negative at 100,000 ng/mL None Detected Negative at 100,000 ng/mL None Detected

# Cocaine-(C0C) (Benzoylecgonine) 150 ng/mL

# Result

Cocaine

Positive at 250 ng/mL

% Cross-Reactive 60%

Ecgonine Ecgonine Methyl Ester

Negative at 100,000 ng/mL Negative at 100,000 ng/mL

None Detected None Detected

# Methamphetamine-(mAMP) (d-Methamphetamine) 500 ng/mL

# Result

Ephedrine   
Fenfluramine   
MDE (MDEA)   
MDMA   
1-Methamphetamine   
Phenethylamine   
Phenylephrine   
Procaine

Positive at 2,500 ng/mL Positive at 50,000 ng/mL Positive at 7,500 ng/mL Positive at 1,150 ng/mL Positive at 7,500 ng/mL Positive at 2,500 ng/mL Positive at 25,000 ng/mL Positive at 7,500 ng/mL

% Cross-Reactive   
20%   
1%   
7%   
$43 \%$   
E $7 \%$   
EY $20 \%$ EY   
E $2 \%$   
$7 \%$ EPY d-Amphetamine l-Amphetamine   
MDA   
Phentermine   
Phenmetrazine ; Pseudoephedrine Tyramine

Negative at 100,000 ng/mL None Detected Negative at 100,000 ng/mL None Detected Negative at 100,000 ng/mL None Detected Negative at 100,000 ng/mL None Detected Negative at 100,000 ng/mL None Detected Negative at 100,000 ng/mL None Detected Negative at 100,000 ng/mL None Detected

# Result

Methadone-(MTD) (Methadone) 200 ng/mL Buprenorphine (MTD Replacement) EDDP (Primary metabolite) EMDP (Secondary metabolite)

% Cross-Reactive None Detected None Detected None Detected

Negative at 100,000 ng/mL Negative at 100,000 ng/mL Negative at 100,000 ng/mL

# Opiates-(0P1) (Morphine) 100 ng/mL

# Result

# % Cross-Reactive

Codeine   
Diacetylmorphine   
Dihydrocodeine   
Ethylmorphine   
Hydrocodone   
Hydromorphone   
Levorphanol   
6-Monoacetylmorphine   
Morphine 3- $\beta$ -D-Glucuronide   
Morphine 6 $\boldsymbol { \cdot } \boldsymbol  \mathsf  \{ \{ \beta $ -D-Glucuronide   
Nalorphine   
Norcodeine   
Thebaine

Positive at 50 ng/mL Positive at $5 0 n g / m L$ EPY Positive at $7 5 n g / m L$ EPY Positive at 50 ng/mL Positive at 400 ng/mL Positive at 800 ng/mL Positive at 2;500 ng/mL Positive at 350 ng/mL Positive at 75 ng/mL Positive at 500 ng/mL Positive at 50,000 ng/mL Positive at 10,000 ng/mL Positive at 25,000 ng/mL

200% 200% 133% 200% 25% 13% 4% 29% 133% 20% $< 1 \%$ EPY EPY $1 \%$ $< 1 \%$ EPY

Apomorphine Naloxone Naltrexone Oxycodone Oxymorphone

Negative at $1 0 0 , 0 0 0 ~ \mathsf { n g / m L }$ EPY None Detected Negative at 100,000 ng/mL None Detected Negative at 100,000 ng/mL None Detected Negative at 100,000 ng/mL None Detected Negative at 100,000 ng/mL None Detected

# Phencyclidine-(PCP) (Phencyclidine) 25 ng/mL

Result Positive at 7,500 ng/mL

4-Hydroxyphencyclidine

% Cross-Reactive $< 1 \%$

# Cannabinoids-(THC) (11-Nor-9-carboxy-4°-THC) 50 ng/mL

# Result

$\Delta ^ { 9 }$ —Tetrahydrocannabinol% Cross-Reactive $< 1 \%$ EPY

Positive at 100,000 ng/mL

Cannabidiol   
Cannabinol   
L-11-Hydroxy $. \Delta 9 .$ THC   
$\Delta 8$ -Tetrahydrocannabinol

Negative at 100,000 ng/mL Negative at 100,000 ng/mL Negative at 100,000 ng/mL Negative at 100,000 ng/mL

None Detected None Detected None Detected None Detected

# Interference Data

# pH and Specific Gravity:

The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System was assayed with three negative clinical samples with pH values of 4.0, 7.0 and $9 . 0 \pm 0 . 1$ . Each sample was assayed in triplicate. The pH samples were fortified with drug concentrations that were the maximum level to give a strong negative $(9 5 \%$ or greater negative) result ( $10 \%$ of cut-off, see Sensitivity data), and the minimum level above the cut-off to give a strong positive $( 9 5 \%$ or greater positive) result $( 1 2 5 - 1 5 0 \%$ of cut-off, see Sensitivity data). All three pH samples gave negative results when fortified to the maximum strong negative level for each drug, and all gave positive results when fortified to the minimum strong positive level for each drug.

The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System was assayed with three samples with specific gravity values of 1.003, 1.015 and $1 . 0 3 0 \pm 0 . 0 0 1$ . Each sample was assayed in triplicate. The specific gravity samples were fortified with drug concentrations as described above for pH to give strong negative and strong positive results. All three specific gravity samples gave negative results when fortified to the maximum strong negative level for each drug, and all gave positive results when fortified to the minimum strong positive level for each drug.

# Common Drugs:

Drug free urine samples were spiked with drug concentrations that were the maximum level to give a strong negative $9 5 \%$ or greater negative) result ( $10 { - } 5 0 \%$ of cut-off, see Sensitivity data), and the minimum level above the cut-off to give a strong positive $( 9 5 \%$ or greater positive) result $( 1 2 5 - 1 5 0 \%$ of cut-off, see Sensitivity data). 100,000 ng/mL of the common drugs were then added to the preparation and assayed by the PROFILE $\textcircled { 8 } - V$ MEDTOXScan® Drugs of Abuse Test System. If a common compound name is followed by the abbreviation "CoC", "BAR" or "OPl", then it has cross-reactivity to the specified drug test (see "Related Compounds and Cross Reactants") and therefore was not assayed for interference for that drug test. Samples were evaluated in triplicate by in-house operators.None of the common drugs listed in the following table affected the expected results.

Table 3. Common Drugs Evaluated with the PROFILE® V MEDTOXScan® Drugs of Abuse Te:   

<table><tr><td rowspan=1 colspan=1>Acetylsalicylic Acid</td><td rowspan=1 colspan=1>Chlorpheniramine</td><td rowspan=1 colspan=1>Morphine - OPI</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>Cocaine - COC</td><td rowspan=1 colspan=1>Phenobarbital - BAR</td></tr><tr><td rowspan=1 colspan=1>Brompheniramine maleate</td><td rowspan=1 colspan=1>Dextromethorphan</td><td rowspan=1 colspan=1>Phenytoin (Diphenylhydantoin)-BAR</td></tr><tr><td rowspan=1 colspan=1>Caffeine</td><td rowspan=1 colspan=1>Doxylamine</td><td rowspan=1 colspan=1>d-Pseudoephedrine</td></tr><tr><td rowspan=1 colspan=1>Carbamazepine</td><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>Salicylic Acid</td></tr></table>

# Discussion of Clinical Tests Performed for Determination of Substantial Equivalence:

The accuracy of the PROFILE®-V MEDTOXScan® Drugs of Abuse Test System was evaluated by assaying a panel of blind coded clinical urine samples containing varying concentrations of drugs and comparing to GC/MS or LC/MS/MS results. The samples were obtained from MEDTOX Laboratories and grouped in the following manner: Negative samples that screened negative by KIMs (Kinetic Interaction of Microparticles in Solution), and not confirmed by GC/MS; Below Cutoff Negative samples that fell between limit of detection or quantitation and $50 \%$ of cutoff; Near Cutoff Negative samples that fell between $50 \%$ of the cutoff concentration and the cutoff concentration; Near Cutoff Positive samples that fell between the cutoff concentration and $150 \%$ of the cutoff concentration; and High Positive samples that were greater than $150 \%$ of cutoff concentration. Drug concentrations were assayed by GC/Ms or LC/MS/Ms for Bzo. Concentrations used to assign the cutoff ranges for each drug were determined by summing the GC/MS and LC/Ms/MS levels measured for all test-specific analytes found in the sample. The testing was performed by in-house operators. The results were interpreted at ten (10) minutes by the MEDTOxScan® reader. No false positives were observed in the absence of drug. The results are summarized in Table 4 below.

Table 4. PROFILE®-V MEDTOXScan® Drugs of Abuse System Results vs stratified GC/MS or LC/MS/MS Values   

<table><tr><td rowspan=1 colspan=1>DRUG</td><td rowspan=1 colspan=1>P-VMEDTOXScanTest System</td><td rowspan=1 colspan=1>NoDrug</td><td rowspan=1 colspan=1>Low negativeby GC/MS orLC/MS/MS(Less than-50%)</td><td rowspan=1 colspan=1>Near CutoffNegative(between-50% andcutoff</td><td rowspan=1 colspan=1>Near CutoffPositive(Betweencutoff and+50%</td><td rowspan=1 colspan=1>HighPositive(greaterthan+50%)</td><td rowspan=1 colspan=1>%Agreement.</td></tr><tr><td rowspan=2 colspan=1>AMP(500)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>96%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>92%</td></tr><tr><td rowspan=2 colspan=1>BAR(200)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>94%</td></tr><tr><td rowspan=2 colspan=1>BZO(150)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>98%</td></tr><tr><td rowspan=2 colspan=1>coc(150)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>97%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>97%</td></tr><tr><td rowspan=2 colspan=1>mAMP(500)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>98%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>98%</td></tr><tr><td rowspan=2 colspan=1>MTD(200)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>98%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>96%</td></tr><tr><td rowspan=2 colspan=1>OPI(100)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>94%</td></tr><tr><td rowspan=2 colspan=1>PCP(25)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>93%</td></tr><tr><td rowspan=2 colspan=1>THC(50)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>96%</td></tr><tr><td rowspan=2 colspan=1>AllDrugs</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>357</td><td rowspan=1 colspan=1>98.5%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>382</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>95.3%</td></tr></table>

For samples giving preliminary positive results below the cutoff and negative results above the cutoff, the assayed values are detailed in the table below:

Table 5. ACCURACY/SUMMARY of DISCORDANT RESULTS   

<table><tr><td rowspan=2 colspan=1>CutoffValue(ng/mL)</td><td rowspan=2 colspan=1>P-VMEDTOXScan TestSystem</td><td rowspan=1 colspan=1>.      Drug or Metabolite</td></tr><tr><td rowspan=1 colspan=1>GC/MS or LC/MS/MS Value (ng/mL)</td></tr><tr><td rowspan=6 colspan=1>500</td><td rowspan=1 colspan=1>AMP positive</td><td rowspan=1 colspan=1>Amphetamine at 277ng/mL</td></tr><tr><td rowspan=1 colspan=1>AMP positive</td><td rowspan=1 colspan=1>Amphetamine at 352ng/mL</td></tr><tr><td rowspan=1 colspan=1>AMP positive</td><td rowspan=1 colspan=1>Amphetamine at 368ng/mL</td></tr><tr><td rowspan=1 colspan=1>AMP positive</td><td rowspan=1 colspan=1>Amphetamine at 463ng/mL</td></tr><tr><td rowspan=1 colspan=1>AMP negative</td><td rowspan=1 colspan=1>Amphetamine at 504ng/mL</td></tr><tr><td rowspan=1 colspan=1>AMP negative</td><td rowspan=1 colspan=1>Amphetamine at 667ng/mL</td></tr><tr><td rowspan=3 colspan=1>200</td><td rowspan=1 colspan=1>BAR positive</td><td rowspan=1 colspan=1>Butalbital at 126ng/mL</td></tr><tr><td rowspan=1 colspan=1>BAR positive</td><td rowspan=1 colspan=1>Butalbital at 159ng/mL</td></tr><tr><td rowspan=1 colspan=1>BAR positive</td><td rowspan=1 colspan=1>Butalbital at 184ng/mL</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>BZO positive</td><td rowspan=1 colspan=1>Alprazolam at 146ng/mL</td></tr><tr><td rowspan=4 colspan=1>150</td><td rowspan=1 colspan=1>COC positive</td><td rowspan=1 colspan=1>Benzoylecgonine at 114ng/mL</td></tr><tr><td rowspan=1 colspan=1>COC positive</td><td rowspan=1 colspan=1>Benzoylecgonine at 121ng/mL</td></tr><tr><td rowspan=1 colspan=1>COC negative</td><td rowspan=1 colspan=1>Benzoylecgonine at 180ng/mL</td></tr><tr><td rowspan=1 colspan=1>COC negative</td><td rowspan=1 colspan=1>Benzoylecgonine at 278ng/mL</td></tr><tr><td rowspan=2 colspan=1>500</td><td rowspan=1 colspan=1>mAMP positive</td><td rowspan=1 colspan=1>Methamphetamine at 483ng/mL</td></tr><tr><td rowspan=1 colspan=1>mAMP negative</td><td rowspan=1 colspan=1>Methamphetamine at 554ng/mL</td></tr><tr><td rowspan=3 colspan=1>200</td><td rowspan=1 colspan=1>MTD positive</td><td rowspan=1 colspan=1>Methadone at 148ng/mL</td></tr><tr><td rowspan=1 colspan=1>MTD positive</td><td rowspan=1 colspan=1>Methadone at 176ng/mL</td></tr><tr><td rowspan=1 colspan=1>MTD negative</td><td rowspan=1 colspan=1>Methadone at 250ng/mL</td></tr><tr><td rowspan=3 colspan=1>100</td><td rowspan=1 colspan=1>OPI positive</td><td rowspan=1 colspan=1>Morphine at 51ng/mL</td></tr><tr><td rowspan=1 colspan=1>OPI positive</td><td rowspan=1 colspan=1>Morphine at 79ng/mL</td></tr><tr><td rowspan=1 colspan=1>OPIpositive</td><td rowspan=1 colspan=1>Morphine at 92ng/mL</td></tr><tr><td rowspan=3 colspan=1>25</td><td rowspan=1 colspan=1>PCPpositive</td><td rowspan=1 colspan=1>Phencyclidine at 19ng/mL</td></tr><tr><td rowspan=1 colspan=1>PCPpositive</td><td rowspan=1 colspan=1>Phencyclidine at 21ng/mL</td></tr><tr><td rowspan=1 colspan=1>PCPpositive</td><td rowspan=1 colspan=1>Phencyclidine at 24ng/mL</td></tr><tr><td rowspan=2 colspan=1>50</td><td rowspan=1 colspan=1>THC positive</td><td rowspan=1 colspan=1>11-nor-9-carboxy-Δ9-THC at 35ng/mL</td></tr><tr><td rowspan=1 colspan=1>THC positive</td><td rowspan=1 colspan=1>11-nor-9-carboxy-9-THC at 39ng/mL</td></tr></table>

# Conclusions:

The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System has the same intended use and similar technological characteristics as the predicate device. Moreover, bench testing contained in this submission demonstrates that any differences in their technological characteristics do not raise any new issues of safety or effectiveness. Thus, the PROFILE® -V MEDTOxScan® Drugs of Abuse Test System is substantially equivalent to the predicate device.

# FEB 1 8 2009

MedTox Diagnostics, Inc. c/o Mr. Phillip Hartzog Director, R&D 1238 Anthony Road Burlington, NC 27215

Re: k080635 Trade/Device Name: Profile -V MedToxScan Drugs of Abuse Test System Regulation Number: 21 CFR 862.3100 Regulation Name: Amphetamine test system Regulatory Class: Class II Product Code: DKZ, DIS, JXM, LDJ, DIO, DJC: DJR, DJG, LCM and JQ Dated: January 15, 2009 Received: January 16, 2009

Dear Mr. Hartzog:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the genieral controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or classIII (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Pitle 21, Code of Fedrtal Pegglations $\Ybrace _ { i , \ldots , i } ^ { \prime }$ , Parts $8 0 0$ to 895. In adoition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page - 2

This letter will llow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assisiance atits toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

![](images/23cea0d058739e3b3f086e6060eec48fc981e99c2306f6fcc60cfa0557852925.jpg)

Courtney C. Harper, Ph.D.   
Acting Director   
Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indication for Use

510(k) Number (if known): k080635

Device Name: PROFILE®-V MEDTOXScan $^ \mathrm { \textregistered }$ Drugs of Abuse Test System

Indication For Use:

The PROFILE®-V MEDTOXScan $\mathfrak { P }$ Drugs of Abuse Test System consists of the PROFILE $\textsuperscript { \textregistered }$ V MEDTOXScan $\textsuperscript { \textregistered }$ Test Devices and the MEDTOXScan $^ \mathrm { \textregistered }$ Reader. The PROFILE $\textsuperscript { \textregistered }$ V MEDTOXScan $\textcircled{8}$ Test Devices are one-step immunochromatographic tests for the rapid, qualitative detection of one or more of the following in human urine: Amphetamine, Barbiturates, Benzodiazepines; Cocaine, Methadone, Methamphetamine, Opiates, Phencyclidine and THC (Cannabinoids) or their metabolites. The PROFILE®-V MEDTOXScan $^ \mathrm { \textregistered }$ Test Devices can only be used with the MEDTOXScan® Reader. The MEDTOXScan@® Reader is an instrument used to interpret and report the results of the PROFILE $\textsuperscript { \textregistered }$ V MEDTOXScan $\textsuperscript { \textregistered }$ Test Device. The PROFILF $\textsuperscript { \textregistered }$ V MEDTOXScan $\textsuperscript { \textregistered }$ Test Devices cannot be visually read.

The PROFILE®-V MEDTOXScan $\textsuperscript { \textregistered }$ Drugs of Abuse Test System is for in vitro diagnostic use and is intended for professional use only. It is not intended for use in point-of-care settings.

Concyrrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

# Indication for Use

510(k) Number (if known): k080635

Device Name: PROFILE $\textcircled{8}$ V MEDTOXScan $\textsuperscript { \textregistered }$ Drugs of Abuse Test System

Indication For Use:

The PROFILE $\textcircled{8}$ V MEDTOXScan $\textsuperscript { \textregistered }$ Drugs of Abuse Test System detects drug classes at the following cutoff concentrations:

AMP Amphetamine (d-Amphetamine) 500 ng/mL BAR Barbiturates (Butalbital) 200 ng/mL BZO Benzodiazepines (Nordiazepam) 150 ng/mL COC Cocaine (Benzoylecgonine) 150 ng/mL MAMP Methamphetamine (d-Methamphetamine) 500 ng/mL MTD Methadone (Methadone) $2 0 \dot { 0 } \approx 1 \mathrm { { n g / m L } }$ EMPY OPI Opiates (Morphine) 100 ng/mL PCP Phencyclidine (Phencyclidine) $2 5 ~ \mathrm { \mathfrak { n g / m L } }$ EY THC Cannabinoids (11-nor-9-carboxy-□9-THC) 50 ng/mL

Configurations of the PROFILE®-V MEDTOXScan $\textsuperscript { \textregistered }$ Test Devices may consist of any combination of the above listed drug analytes.

THE PROFILE®-V MEDTOXSCan $\textsuperscript { \textregistered }$ Drugs of Abuse Test System provides only a preliminary analytical result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) or liquid chromatography/tandem mass spectrometry (LC/MS/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are obtained.

The MEDTOXScan® Reader includes a Positive QC Test Device, a Negative QC Test Device and a Cleaning Cassette. The MEDTOXScan $\textsuperscript { \textregistered }$ Positive and Negative QC Test Devices are intended to detect errors associated with the MEDTOXScan $\textsuperscript { \textregistered }$ Reader and a contaminated contact imaging sensor (CIS) and to verify that the CIS cleaning procedure using the MEDTOXScan® Cleaning Cassette effectively removed any contamination.

Concurrence of CDRH, Offce of In Vitro Diagnostic Device Evaluation and.Safety (OIVD)

![](images/36710bb1af1421eaaf89685a440105a478489d61a58fe83f54c0f40bc42ed14c.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety